Table 1 Patient characteristics (N=18)

From: Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma

Age (years)

 

 Median

52.3

 Range

31–77

Sex

 Male

N=8

 Female

N=10

Lymphoma histology

 Follicular

N=10

 Small lymphocytic

N=1

 Malt

N=1

 Transformed

N=6

Stage at study entry

 II

N=3

 III

N=4

 IV

N=11

Bulky tumour (largest diameter⩾5 cm)

N=14

Bone marrow involvement

N=7

Disease evolution from diagnosis to study entry (months)

 Median

31.2

 Mean

45.1

 Range

8–121

Prior chemo-rituximab therapies

 Mean

3.0

 Range

1–6

Previous RT

N=4

Previous rituximab

N=10

Elevated LDH

N=7

Reduced platelet counts

N=4

Back to article page